NASDAQ:AMGN • US0311621009
Taking everything into account, AMGN scores 5 out of 10 in our fundamental rating. AMGN was compared to 521 industry peers in the Biotechnology industry. While AMGN has a great profitability rating, there are quite some concerns on its financial health. AMGN has a correct valuation and a medium growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.51% | ||
| ROE | 89.06% | ||
| ROIC | 16.85% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.19% | ||
| PM (TTM) | 20.98% | ||
| GM | 73.3% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.78 | ||
| Debt/FCF | 6.74 | ||
| Altman-Z | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 0.9 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.19 | ||
| Fwd PE | 16.67 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.97 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.62% |
NASDAQ:AMGN (2/20/2026, 11:14:03 AM)
375.615
+0.12 (+0.03%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.62% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.19 | ||
| Fwd PE | 16.67 | ||
| P/S | 5.5 | ||
| P/FCF | 24.97 | ||
| P/OCF | 20.31 | ||
| P/B | 23.36 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.51% | ||
| ROE | 89.06% | ||
| ROCE | 19.3% | ||
| ROIC | 16.85% | ||
| ROICexc | 19.6% | ||
| ROICexgc | 73.08% | ||
| OM | 34.19% | ||
| PM (TTM) | 20.98% | ||
| GM | 73.3% | ||
| FCFM | 22.04% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.78 | ||
| Debt/FCF | 6.74 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 5.06% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 105.05% | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 0.9 | ||
| Altman-Z | N/A |
ChartMill assigns a fundamental rating of 5 / 10 to AMGN.
ChartMill assigns a valuation rating of 5 / 10 to AMGEN INC (AMGN). This can be considered as Fairly Valued.
AMGEN INC (AMGN) has a profitability rating of 8 / 10.
The financial health rating of AMGEN INC (AMGN) is 3 / 10.
The Earnings per Share (EPS) of AMGEN INC (AMGN) is expected to grow by 3.12% in the next year.